Stock screener

ANAB

Conviction 27HealthcareScan · Mon, Aug 10, 2026
ANAB$55.45-2.05%
ResistanceSupportVol 14
63 bars
Vol MA14 538.44K
May 11May 28Jun 16Jul 6Jul 23Aug 10
ANAPTYSBIO, INCPHARMACEUTICAL PREPARATIONSwww.anaptysbio.com
Price55.45
Change-2.05%
Gap-0.11%
Rel volume0.75×
Avg volume691.35K
Avg $ vol37.71M
SMA 2054.65
SMA 5057.28
SMA 20053.34
Price vs 50-3.20%
Price vs 200+3.95%
MA stackmixed
50/200 cross
Supertrenddown · 63.57
RSI (14)48
MACD hist0.34
MACD crossbull · 3d
Stoch %K / %D60 / 68
ADX (14)12
+DI / −DI24 / 16
RSI divergence
MACD divergence
ATR %+6.11%
ADR %6.54%
52w high70.22
52w low19.40
From 52w high-21.03%
Above 52w low+185.82%
New 52w highNo
SqueezeOff
Bollinger width17.96%
%B0.58
Donchian pos27.08%
Donchian high70.91
Donchian low49.71
AVWAP (52w high)59.61
vs AVWAP high-6.97%
AVWAP (52w low)50.61
vs AVWAP low+9.57%
OBV trendDown
Chaikin MF (20)-0.12
Today vs 20d0.75×
Avg vol (14d)538.43K
Avg vol (20d)691.35K
Avg $ vol (20d)37.71M
Market cap1.61B
RS 3m (vs SPY)-21.15%
RS 6m (vs SPY)+4.07%
RS line new highNo
Trend template4/8
Technical rank45.3
1 week+3.34%
1 month-16.48%
3 months-20.02%
6 months+11.50%
1 year+172.21%
YTD+23.36%
P/E-121.95
P/B126.59
P/S6.88
P/FCF82.29
EPS-0.4600
Div yield
ROE-103.80%
ROA-4.01%
Debt/Eq
Current7.58
EV/EBITDA28.17
Gross margin
Net margin-5.64%
Rev growth157.01%
EPS growth90.89%
Price target80.67
Target upside45.48%
Analyst ratingBuy
Institutional102.57%
Ent. value1.37B
Revenue25.56M
Net income-52.88M
Gross profit
Free cash flow19.61M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out29.1M
Employees104
ListedThu, Jan 26, 2017
Free float17.05M
Float %61.6%
Short interest5M
Days to cover5.9d
Short volume76.8%
Squeeze score85 / 100
Next earnings
EPS forecast
Last EPS vs est−$1.84 vs −$0.32
Last surprise-475.0% miss
Setup gradeD
Conviction27 / 100
Pattern quality
Tech rank45.3 / 100
Group rank86 / 100 · Leading
Status laneNo active setup
Setup direction
Pattern family
Resistance70.09
Support50.11
Days since event
Candle confirm
News sentiment

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in ANAB

All disclosures →
No recent disclosed trades by Congress in ANAB. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in ANAB · 7 buys · 3 sells

InsiderSideShares
Faga Daniel
President, CEO · Performance Stock Units · 2026-03-12
Grant53.33K
Lizzul Paul F.
Chief Medical Officer · Performance Stock Units · 2026-03-12
Grant16.67K
RENTON HOLLINGS
Director · Common Stock · 2026-06-15
Exercise6.03K
RENTON HOLLINGS
Director · Restricted Stock Unit · 2026-06-15
Exercise6.03K
Orwin John A
Director · Common Stock · 2026-06-15
Exercise6.03K
Orwin John A
Director · Restricted Stock Unit · 2026-06-15
Exercise6.03K
Schmid John P.
Director · Common Stock · 2026-06-15
Exercise6.03K
Schmid John P.
Director · Restricted Stock Unit · 2026-06-15
Exercise6.03K
Murphy Christopher M.
Chief Financial Officer · Restricted Stock Units · 2026-05-11
Grant25.77K
Hughes Owen
Director · Restricted Stock Units · 2026-05-11
Grant11.25K

SEC filings

EDGAR filings in ANAB · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.